

- But a1*
- C) cationic pluronics which are block copolymers or surfactants which are positively charged, in particular with NH_2^+ groups
- D) complexing agents which form complexes with fatty acids such as deoxycholic acid, or
- E) cyclodextrins and their derivatives such as dimethyl β cyclodextrin.

0993705500502660

5. (Amended) A composition according to claim 1 wherein the carrier comprises a particle.

a2

10. (Amended) A composition according to claim 7 wherein the microsphere comprises poly-(L-lactide).

11. (Amended) A composition according to claim 1 wherein the ratio of the chemical (ii) to the carrier is from 99:1 to 9:1 w/w.

12. (Amended) A composition according to claim 1 which is adapted for administration to a mucosal surface or is suitable for parenteral administration.

a3

15. (Amended) A method of protecting a mammal against infection, which method comprises administration of a composition according to claim 1 to a mammal.

24

 a^5

John W. Krumm

TO THE HONORABLE

3. (Amended) A composition according to claim 1 [or claim 2] wherein the said adjuvant chemical can act as an immunostimulant.

A) poly-ornithine, for example of molecular weight from 5 to 150kDa;

B) water soluble vitamins or vitamin derivatives such as vitamin E TPGS (d-alpha tocophenyl polyethylene glycol 1000 succinate),

D) complexing agents which form complexes with fatty acids such as deoxycholic acid, or

E) cyclodextrins and their derivatives such as dimethyl β cyclodextrin.

5. (Amended) A composition according to [any one of the preceding] claim[s]
1 wherein the carrier comprises a particle.

1227938

Express Mail Label No. EL209599012US
U.S. National Phase Entry of PCT/GB00/01104
"Vaccine Composition"
Filed: 20 September 2001
PRELIMINARY AMENDMENT

11. (Amended) A composition according to [any one of the preceding] claim[s]
1 wherein the ratio of the chemical (ii) to the carrier is from 99:1 to 9:1 w/w.

12. (Amended) A composition according to [any one of the preceding] claim[s]
1 which is adapted for administration to a mucosal surface or is suitable for parenteral
administration.

15. (Amended) A method of protecting a mammal against infection, which
method comprises administration of a composition according to [any one of] claim[s] 1 [to
13] to a mammal.

20. (Amended) A microsphere according to claim 18 [or claim 19] which
further comprises an agent that is capable of generating a protective immune response in an
animal to which it is administered.

22. (Amended) A pharmaceutical composition comprising a microsphere
according to [any one of] claim[s] 19 [to 22].